Pure Global Cannabis Inc. through its subsidiary PureSinse Inc., has announced Health Canada has issued the latter a sales licence under the Cannabis Act.

Eligible and pre-registered Canadian medical patients can soon select from two dozen premium cannabis products offered by PureSinse, via its newly launched eCommerce website at PureSinse.com.

“The company is committed to supporting medical cannabis patients by emphasizing the quality of, and access to, the products they need,” notes a press release from Pure Global Cannabis, an integrated, growth-oriented life sciences and consumer products cannabis company. The statement further points out the company anticipates growing to 70 stock-keeping units, including extracted oil products and vape products, by mid-2019.

Calling the licence a significant milestone, “we feel the medical community has been hugely underservised with poor patient and physician education, and product offerings, areas we hope to be trail-blazers in and make a significant contribution to in 2019,” says Malay Panchal, CEO of Pure Global.

“As part of the sales licence, the company can also sell products into the adult-legal consumer market through provincially licensed retailers, for which it is launching uniquely curated lines of consumer products tailored to specific market segments,” the statement notes.

That said, the commitment to the medical community is demonstrated by the company leading “one of the largest, real-world evidence-based, clinical studies in conjunction with the Appletree Medical Group and one of the largest clinical research organizations in the world,” the press release states.

“The clinical data, which will be collected from thousands of patients, will provide necessary data points for guidance in the therapeutic benefits of specific cannabis strains for commonly reported medical symptoms,” the statement notes, adding that findings “will guide PureSinse’s future pharmaceutical product and consumer product development plans and provide the medical community with published peer-reviewed observational data on the efficacy of medical cannabis for a range of conditions.”